The reaction of cyanoacetylhydrazine with chloroacetyl chloride gave N'-(2-chloroacetyl)-2-cyanoacetohydrazide. The latter underwent cyclization to afford 1-(5 amino-3-hydroxy-1H-pyrazol-1-yl)-2-chloroethanone, which underwent nucleophilic substitution to give 3-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-3-oxopropanenitrile. The latter two compounds were used as key synthons to synthesize new thiophene, pyran, thiazole and some fused heterocyclic derivatives. The antitumor activity of the newly synthesized compounds was evaluated against three human tumor cells lines, namely breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268) and some of these compounds were found to exhibit much higher inhibitory effects towards the three tumor cell lines than the Gram positive control doxorubicin.
Introduction
Cancer is a major public health problem in the world. Chemotherapy is still one of the primary modalities for the treatment of cancer. However, the use of this method is limited mainly due to the small number of the available chemotherapeutic agents to choose among them and also because the use of these agents is often accompanied by undesirable side effects. This clearly underlies the urgent need for developing novel chemotherapeutic agents with more potent antitumor activities and reduced side effects.
Many pyrazole derivatives have attracted considerable attention in the recent years for their diverse biological activities [1] [2] [3] [4] [5] [6] . They are also acknowledged for their anticancer activities [7] [8] [9] . Moreover, the chemistry of fused pyrazolo-and thieno-pyrazole derivatives has drawn great attention due to their pharmacological importance [10] [11] [12] . Such excellent pharmacology encouraged us to synthesize novel pyrazole derivatives with evaluation of their antitumor activities.
Results and Discussion

Chemistry
The starting material, N'-(2-chloroacetyl)-2-cyanoacetohydrazide (3) was prepared by reacting cyanoacetylhydrazine (1) with chloroacetyl chloride (2) in 1,4-dioxane. Structural elucidation of compound 3 was based on its 1 H-NMR and 13 C-NMR data. Thus, the 1 H-NMR spectrum showed the presence of two singlets at δ 3.51, 4.05 ppm indicating the presence of the two CH 2 groups and two broad singlets at δ 8.22-8.26 ppm corresponding to the two NH groups. Moreover, the 13 C-NMR spectrum revealed the presence of the following signals at δ: 25.8, 40.8 (2 CH 2 ), 116.8 (CN), 162.3, 168.9 (2 C=O).
Heterocyclization of N-α-halocarbonyl derivatives using sodium ethoxide has been previously reported [13] [14] [15] [16] [17] . Thus, compound 3 readily underwent cyclization when heated in sodium ethoxide solution to give 1-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-2-chloroethanone (4). The IR spectrum of this compound indicated the presence of OH and NH 2 groups at 3583-3305 cm −1 and C=O at 1693 cm −1 . Furthermore the 1 H-NMR spectrum revealed the presence of a singlet δ at 4.51 ppm, a singlet at δ 4.88 ppm, a singlet at δ 6.89, and a singlet at δ 10.36 ppm (D 2 O exchangeable) corresponding to the CH 2 , NH 2 , the pyrazole H-4 and the OH group protons, respectively. Compound 4 was converted to the corresponding N-carbonylacetonitrilopyrazole derivative 5 by nucleophilic substitution of the chlorine atom using potassium cyanide. Subjecting compound 5 to the Gewald thiophene synthesis [18] [19] [20] [21] [22] via its reaction with either malononitrile (6a) or ethyl cyanoacetate (6b) and elemental sulfur in presence of triethylamine as basic catalyst afforded the pyrazol-1-yl N-thiophen-5-yl derivatives 7a and 7b, respectively. On the other hand, the reaction of compound 5 with cyclohexanone and elemental sulfur in presence of triethylamine as basic catalyst afforded the (5-amino-3-hydroxy-1H-pyrazol-1-yl)(2-amino-4,5,6,7-tetrahydrobenzo-[b]thiophen-3-y0,l)methanone derivative 8 (Scheme 1). The analytical and spectroscopic data of compounds 7a,b and 8 are consistent with the proposed structures (see Experimental section). Thus, the 1 H-NMR spectrum of compound 8 showed the presence of two multiplets at δ 2.23-2.27 ppm indicating the presence of the four CH 2 , two singlets at δ 4.49, 4.80 ppm indicating the presence of two NH 2 groups, a singlet at δ 6.89 ppm indicating the pyrazole H-4 and a singlet at δ 10.23 ppm corresponding to the OH group. Moreover, the The reaction of compound 5 with benzaldehyde (9) gave the phenylmethylidene derivative 10. The latter showed interesting reactivity towards cyanomethylene reagents, namely malononitrile (6a) and ethyl cyanoacetate (6b) and afforded the pyrazole-1-yl-pyran derivatives 11a and 11b, respectively. The latter products underwent ready cyclization in sodium ethoxide solution to give the dihydropyrazolo [1,5-a] Finally, the reactivity of compound 4 as an α-halocarbonyl compound to produce thiazole derivatives was investigated. Thus, the reaction of the active methylene reagents 6a,b and 15a,b with 
Antitumor Evaluations
Structure Activity Relationship of the Newly Synthesized Products
The effect of the newly synthesized products was evaluated on the in-vitro growth of three human tumor cell lines representing different tumor types, namely, breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460) and CNS cancer (SF-268), after a continuous exposure of 48 h. The results are summarized in Table 1 . Results are given in concentrations that were able to cause 50% of cell growth inhibition (GI 50 ) after a continuous exposure of 48 h and show means ± SEM of three-independent experiments performed in duplicate All the compounds were able to inhibit the growth of the human tumor cell lines in a dose-dependentmanner. 5,8-Diamino-7-cyano-2-hydroxy-6-phenyl-6,7-dihydro1,5α pyrano [2,3- 
pentane-2,4-dione (18c) showed the best results, exhibiting the highest inhibitory effects of the tested compounds towards the three tumor cell lines, which are higher than that of the reference compound doxorubicin. On the other hand, compounds 17a, 17d, and 18d showed high growth inhibitory effect but such activity are lower than the reference, doxorubicin. Comparing the activities of 11a and 11b indicated that the presence of the CN group in 11a resulted a stronger growth inhibitory effect than COOC 2 H 5 group in compound 11b. Similarly comparing the reactivity of compounds 12a and 12b indicated that the presence of the CN group in 12a also is responsible of its higher reactivity over 12b. On the other hand, compound 17a with the CN group is the most active compound towards the three cancer cell lines among the pyrazole derivatives 17a-d, of course the presence of the CN group in 17a is responsible for such high activity. On the other hand, compound 17c where X = Y = COCH 3 is of lower activity than 17d with X = COCH 3 & Y = COOC 2 H 5 . Finally it worthy to refer to observation that indicated also that compound 18a showed the highest reactivity towards the three cancer cell line among compound 8a-d. On the other hand, compounds 5, 7a, 7b, 10 and 14 exhibited the lowest reactivity towards the cancer cell lines.
Experimental
Antitumor Activity Tests
Reagents: Fetal bovine serum (FBS) and L-glutamine, were from Gibco Invitrogen Co. (Oxford, UK). RPMI-1640 medium was from Cambrex (Ashland, NJ, USA). Dimethyl sulfoxide (DMSO), doxorubicin, penicillin, streptomycin and sulforhodamine B (SRB) were obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Cell cultures: Three human tumor cell lines, MCF-7 (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), and SF-268 (CNS cancer) were used. MCF-7 was obtained from the European Collection of Cell Cultures (ECACC, Salisbury, UK) and NCI-H460 and SF-268 were kindly provided by the National Cancer Institute (NCI, Cairo, Egypt). They grow as monolayer and routinely maintained in RPMI-1640 medium supplemented with 5% heat inactivated FBS, 2 mM glutamine and antibiotics (penicillin 100 U/mL, streptomycin 100 μg/mL), at 37 °C in a humidified atmosphere containing 5% CO 2 . Exponentially growing cells were obtained by plating 1.5 × 10 5 cells/mL for MCF-7 and SF-268 and 0.75 × 10 4 cells/mL for NCI-H460, followed by 24 h of incubation. The effect of the vehicle solvent (DMSO) on the growth of these cell lines was evaluated in all the experiments by exposing untreated control cells to the maximum concentration (0.5%) of DMSO used in each assay.
Tumor cell growth assay: The effects of compounds 3-18a-d on the in-vitro growth of human tumor cell lines were evaluated according to the procedure adopted by the National Cancer Institute (NCI, Cairo, Egypt). In the 'in-vitro Anticancer Drug Discovery Screen' that uses the protein-binding dye sulforhodamine B to assess cell growth [28] . Briefly, cells growing exponentially in 96-well plates were then exposed for 48 h to five serial concentrations of each compound, starting from a maximum concentration of 150 M. Following this exposure period adherent cells were fixed, washed, and stained. The bound stain was solubilized and the absorbance was measured at 492 nm in a plate reader (Bio-Tek Instruments Inc., Powerwave XS, Wincoski, San Diego, CA, USA). For each test compound and cell line, a dose-response curve was obtained and the growth inhibition of 50% (GI 50 ), corresponding to the concentration of the compounds that inhibited 50% of the net cell growth, was calculated as described elsewhere [29] . Doxorubicin was used as a positive control and tested in the same manner.
Chemistry
All melting points are uncorrected. IR spectra were recorded for KBr discs on a Pye Unicam SP-1000 spectrophotometer. 
1-(5-Amino-3-hydroxy-1H-pyrazol-1-yl)-2-chloroethanone (4)
.
5-Amino-3-hydroxy-1H-pyrazol-1-yl)(2,4-diamino-3-cyanothiophene-5-yl)methanone(7a)and 5-amino-3-hydroxy-1H-pyrazol-1-yl)(ethyl 2,4-diaminothiophene-5-yl-3-carboxylate)methanone (7b).
General procedure: To a solution of compound 5 (1.66 g, 0.01 mol) in 1,4-dioxane (30 mL) containing triethylamine (1.0 mL) either malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) were added, followed by elemental sulfur (0.32 g, 0.01 mol). The whole reaction mixture, in each case was heated under reflux for 1 h then left to cool then poured onto ice/water mixture containing few drops of hydrochloric acid. The formed solid product, in each case, was collected by filtration. (8) . To a solution of compound 5 (1.66 g, 0.01 mol) in 1,4-dioxane (30 mL) containing triethylamine (1.0 mL), cyclohexanone (0.98 g, 0.01 mol) was added, followed by elemental sulfur (0.32 g, 0.01 mol). The whole reaction mixture was heated under reflux for 2 h then left to cool then poured onto ice/water containing few drops of hydrochloric acid. The formed solid product, in each case, was collected by filtration. Crystallized from acetic acid to give yellow crystals yield (10) . To a solution of compound 5 (1.66 g, 0.01 mol) in 1,4-dioxane (40 mL) containing piperidine (0.50 mL) benzaldehyde (1.06 g, 0.01 mol) was added. The reaction mixture was heated under reflux for 3 h then left to cool. The solid product, so formed, was collected by filtration. Crystalized from ethanol to give pale yellow crystals, yield 1.27 g (50%), m.p. 180-183 °C. Anal. Calculated for C 13 
(5-Amino-3-hydroxy-1H-pyrazol-1-yl)(2-amino-4,5,6,7-tetrahydrobenzo-[b]thiophen-3-yl)-methanone
3-(5-Amino-3-hydroxy-1H-pyrazol-1-yl)-3-oxo-2-benzalydinepropanenitrile
2-Amino-6-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-4-phenyl-4H-pyran-3,5-dicarbonitrile (11a) and ethyl 2-amino-6-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-5-cyano-4-phenyl-4H-pyran-3-carboxylate (11b).
General procedure: To a solution of compound 10 (2.54 g, 0.01 mol) in 1,4-dioxane (30 mL) containing triethylamine (0.50 mL), either malononitrile (0.66 g, 0.01 mol) or ethyl cyanoacetate (1.13 g, 0.01 mol) was added. The resulting reaction mixture in each case was heated under reflux for 6 h then the excess solvent was evaporated under reduced pressure. Amino-3-hydroxy-1H-pyrazol-1-yl)-2-cyano-3-pheny-2-buten-1-one (14) . A mixture of compound 5 (1.66 g, 0.01 mol), acetophenone 13 (1.20 g, 0.01 mol) and ammonium acetate (1.0 g) was heated in an oil bath at 120 °C for 15 min then left to cool to room temperature. The resulting residue was then heated in ethanol (20 mL) 
3-(5-
1-(5-Amino-3-hydroxy-1H
-pyrazol-1-yl)-2-thio(2-cyano-3-phenylamino-acrylonitril-3-yl)-ethanone (17a), 1-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-2-thio(ethyl 2-cyano-3-phenylaminoacrylat-3-yl)ethanone (17b),
1-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-2-thio(2-acetyl-4-phenylamino-but-3-ene-2-one-4-yl)ethanone
(17c) and
1-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-2-thio(ethyl 2-acetyl-3-phenylaminopropenoat-3-yl)ethanone (17d).
General procedure: To a solution of either 6a (0.66 g, 0.01 mol) or 6b (1.13 g, 0.01 mol), 6c (1.0 g, 0.01 mol) or 6d (1.30 g, 0.01 mol) in dimethylformamide (30 mL) containing potassium hydroxide (0.56 g, 0.01 mol), phenylisothiocyanate (1.30 g, 0.01 mol) was added. The whole reaction mixture was stirred at room temperature overnight. On the next day compound 4 (1.75 g, 0.01 mol) was added with continuous stirring overnight at room temperature then poured onto ice/water containing few drops of hydrochloric acid (to pH 6). The solid product, formed in each case, was collected by filtration. 
2-(4-(5-Amino-3-hydroxy-1H-pyrazol-1-yl)-3-phenylthiazol-2(3H)-ylidene)-malononitrile (18a), ethyl 2-(4-(5-aino-3-hydroxy-1H-pyrazol-1-yl)-3-phenylthiazol-2(3H)-ylidene)-2-cyanoacetate (18b), 2-(4-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-3-phenylthiazol-2(3H)-ylidene)pentane-2,4-dione (18c) and ethyl 2-(4-(5-amino-3-hydroxy-1H-pyrazol-1-yl)-3-phenylthiazol-2(3H)-ylidene)-3-oxo-butanoate
